Skip to main content

Dr. An H. Pham, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
39
In the NPI registry since
2006
Medicare patients seen, 2024
1,185

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1987Medical school: Hahnemann University College of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    PA license MD042011E
  • Critical Care Medicine (Internal Medicine) Physician
    PA license MD042011E

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,185
Services billed
80,399
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, mepolizumab, 1 mg18,43424
Injection, omalizumab, 5 mg10,94411
Established patient office or other outpatient visit, 20-29 minutes1,671786
Injection, benralizumab, 1 mg1,29211
Injection of drug or substance under skin or into muscle1,071184
Test to measure expiratory airflow and volume835533
Established patient office or other outpatient visit, 30-39 minutes530292
Test to determine lung volumes using gas dilution or washout480423
Test to examine how well the lungs exchange gases472418
Injection, methylprednisolone acetate, 80 mg280153

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 30 companies reported 297 payments worth $6,587 in total to this clinician.

By company
AstraZeneca Pharmaceuticals LP$1,322
Verona Pharma, Inc.$720
Genzyme Corporation$710
GlaxoSmithKline, LLC.$396
Harmony Biosciences LLC$334
Mallinckrodt Hospital Products Inc.$308
Insmed, Inc.$299
Actelion Pharmaceuticals US, Inc.$295
By type
Food and Beverage$6,137
Consulting Fee$350
Education$99.95

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 30, 2025Bayer HealthCare Pharmaceuticals Inc.
Sep 30, 2025
Consulting Fee
Adempas · Cardio-pulmonary
$200
Jan 17, 2025Avadel Cns Pharmaceuticals, LLC
Jan 17, 2025
Consulting Fee
LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY
$150
Jul 15, 2025Sanofi-aventis U.S. LLC
Jul 15, 2025
Education
DUPIXENT · Immunology · in-kind
$99.95

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $125,663 in research payments for these studies, mostly to the institutions running them.

  • A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
    AstraZeneca Pharmaceuticals LP
  • Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
    Sanofi US Services Inc. · Completed · NCT06102005
  • Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
    AstraZeneca Pharmaceuticals LP
  • A randomized, double-blind, parallel group, multi-center study to eval
    GlaxoSmithKline, LLC.
  • A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Pottstown

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 17, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1609848456. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.